VEGFA and rheumatoid arthritis: More recent studies have investigated in an experimental RA model the effect of anti-VEGF therapy (ranibizumab, anti-VEGF antibody; ramucirumab, monoclonal antibody against VEGFR2), in monotherapy or in combination with current therapy (methotrexate or tocilizumab treatment), and the authors found that anti-VEGF reduced bone and cartilage destruction [22,23].